First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

MLA

Ignacio I Wistuba, et al. “First-in-Human Dose Escalation Trial to Evaluate the Clinical Safety and Efficacy of an Anti-MAGEA1 Autologous TCR-Transgenic T Cell Therapy in Relapsed and Refractory Solid Tumors.” Journal for ImmunoTherapy of Cancer, vol. 12, no. 7, July 2024. EBSCOhost, https://doi.org/10.1136/jitc-2023-008668.

APA

Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, … Delfi Krishna. (2024). First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Journal for ImmunoTherapy of Cancer, 12(7). https://doi.org/10.1136/jitc-2023-008668

Chicago

Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, et al. 2024. “First-in-Human Dose Escalation Trial to Evaluate the Clinical Safety and Efficacy of an Anti-MAGEA1 Autologous TCR-Transgenic T Cell Therapy in Relapsed and Refractory Solid Tumors.” Journal for ImmunoTherapy of Cancer 12 (7). doi:10.1136/jitc-2023-008668.